ArticleDrug, healthcare and patient safety2026
Capecitabine Dosage as an Independent Prognostic Factor for the Development of Hand-Foot Syndrome: A Competing Risk Analysis.
Article in Drug, healthcare and patient safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Capecitabine, an oral prodrug of 5-fluorouracil, commonly causes hand-foot syndrome (HFS). Although clinical predictors of HFS have been reported, causal evidence supporting dosage as an independent prognostic factor remains limited. Because competing events may preclude HFS, this study evaluated the prognostic role of capecitabine dosage in grade 2-3 HFS using a competing risk analysis. Patients and Methods: A retrospective observational cohort study was conducted. Capecitabine dosage was the exposure of interest. Potential confounders including sex, combination chemotherapy, and estimated glomerular filtration rate (eGFR) were identified using a directed acyclic graph. The primary endpoint was time from treatment initiation to grade 2-3 HFS. A multivariable competing risk analysis was performed using the Lambert model, with loss to follow-up, severe diarrhea, sepsis, and death defined as competing events. Capecitabine dosage was categorized (2000-4000 mg/day) to facilitate clinical interpretability. Results: Among 596 patients, 132 (22.2%) developed grade 2-3 HFS, with a median onset time of 63 days (interquartile range, 42-84). Higher capecitabine dosage was independently associated with an increased risk of HFS, with the greatest effect observed at 4000 mg/day compared with 2000 mg/day (aHR 4.41; 95% CI, 1.31-14.81; p = 0.016), demonstrating a clear dose-dependent increase in risk. In addition, higher dosage was associated with a shorter model-predicted median time to HFS onset. Conclusion: This study confirms capecitabine dosage as an independent prognostic factor for grade 2-3 HFS, with significantly increased risk at 4000 mg/day and a shorter median time to HFS onset as dosage increases. These findings underscore the importance of careful dosing and support the implementation of evidence-based strategies for dose adjustment in high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.